As we recently reported, a last-minute rider was slipped into HR 933, the 240-page spending bill signed by President Barack Obama on March 26. The bill was designed as an emergency measure to prevent a government shutdown, but as it turned out, it also made a pretty good Trojan horse for the biotech industry.